CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Engineering strategies to optimise adoptive cell therapy in ovarian cancer.
Engineering strategies to optimise adoptive cell therapy in ovarian cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
卵巢癌是女性最常见的十种癌症之一，也是主要死亡原因之一。抗血管生成药物和聚腺苷二磷酸核糖聚合酶抑制剂（PARPi）等靶向疗法虽取得令人鼓舞的结果，但多数患者仍会复发并产生治疗耐药，提示需要新的治疗策略。过继细胞治疗（ACT）是利用自体免疫细胞清除癌症的过程，包括TIL（肿瘤浸润淋巴细胞）、经T细胞受体（TCR）基因工程改造的T细胞以及嵌合抗原受体（CAR）T细胞。近年来，ACT治疗血液系统恶性肿瘤显示出良好前景，但其在实体瘤中的应用仍受限于T细胞功能和持续性不足、耗竭表型常见及肿瘤微环境（TME）内迁移受损。本文综述ACT治疗卵巢癌的潜力，并探讨克服其主要局限的策略。
Ovarian cancer is amongst the ten most common cancer types in women, and it is one of the leading causes of death. Despite the promising results of targeted therapies, including anti-angiogenic agents and poly (ADP-ribose) polymerase inhibitors (PARPi), the majority of patients will relapse and develop treatment resistance, implying that novel therapeutic strategies are required. Adoptive cell therapy (ACT) refers to the process by which autologous immune cells are used to eliminate cancer.
Examples include tumour infiltrating lymphocytes (TILs), T cells genetically engineered with T cell receptors (TCR), or chimeric antigen receptor (CAR)-T cells.
Recently, ACT has revealed promising results in the treatment of haematological malignancies, however, its application to solid tumours is still limited due to lack of functionality and persistence of T cells, prevalence of an exhausted phenotype and impaired trafficking towards the tumour microenvironment (TME). In this review we explore the potential of ACT for the treatment of ovarian cancer and strategies to overcome its principal limitations.
MEMBER ACCOUNT
登录成功会直接打开下一页。
